AIM
TVTX icon

Assured Investment Management’s Travere Therapeutics TVTX Stock Holding History

Assured Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-30,550
Closed -$691K – 797
2019
Q1 		$691K Buy
30,550
+20,511
+204% +$453K 0.01% 482
2018
Q4 		$227K Buy
10,039
+3,328
+50% +$82.8K 0.01% 861
2018
Q3 		$193K Sell
6,711
-14,056
-68% -$402K ﹤0.01% 972
2018
Q2 		$566K Sell
20,767
-11,269
-35% -$300K 0.01% 779
2018
Q1 		$716K Buy
+32,036
New +$763K 0.02% 655

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Assured Investment Management's TVTX Position: Q2 2019 in Review

Assured Investment Management sold out of Travere Therapeutics (TVTX) in Q2 2019, closing a stake of 30,550 shares — an estimated $691K sold.

Assured Investment Management first reported a position in TVTX in Q1 2018 and held it in 5 quarters. The position peaked at $716K in Q1 2018. 122 funds tracked by Wall St. Rank hold TVTX as of Q2 2019.

  • Assured Investment Management reported no remaining Travere Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Assured Investment Management sold 30,550 Travere Therapeutics shares in Q2 2019, an estimated $691K.
  • Assured Investment Management first reported a position in Travere Therapeutics in Q1 2018 and held it in 5 quarters.
  • Assured Investment Management's Travere Therapeutics position peaked at $716K in Q1 2018.
  • 122 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2019.

Based on Assured Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.